The CAPItello-281 Trial and FDA Approval of Capivasertib in PTEN-Loss mHSPC - Elisabeth Heath
Elisabeth Heath discusses the FDA approval of capivasertib for PTEN-deficient metastatic hormone-sensitive prostate cancer, reviewing CAPItello-281 data in de novo patients randomized to capivasertib plus abiraterone versus abiraterone alone, both with ADT. The hazard ratio was approximately 0.8, with the control…